חיפוש מתקדם
תחביר
חפש...
הספר "אוצר וולקני"
אודות
תנאי שימוש
ניהול
קהילה:
אסיף מאגר המחקר החקלאי
פותח על ידי קלירמאש פתרונות בע"מ -
Localisation of mesenchymal tumours by somatostatin receptor imaging
Year:
2002
Source of publication :
Lancet
Authors :
שרון, מיכל
;
.
Volume :
359
Co-Authors:
De Jan Beur, S.M., Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, United States
Streeten, E.A., Department of Medicine, University of Maryland, School of Medicine, Baltimore, MD, United States
Civelek, A.C., Department of Nuclear Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, United States
McCarthy, E.F., Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, United States
Uribe, L., Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, United States
Marx, S.J., Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, United States
Onobrakpeya, O., Department of Medicine, University of Connecticut Health Center, Farmington, CT, United States
Raisz, L.G., Department of Medicine, University of Connecticut Health Center, Farmington, CT, United States
Watts, N.B., Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, OH, United States
Sharon, M., Department of Medicine, Washington Hospital Center, Washington, DC, United States
Levine, M.A., Department of Pediatrics, Ilyssa Center for Molecular and Cellular Endocrinology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States
Facilitators :
From page:
761
To page:
763
(
Total pages:
3
)
Abstract:
Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.
Note:
Related Files :
clinical article
fibroblast growth factor 23
indium 111
Indium Radioisotopes
pentetreotide
sensitivity and specificity
unclassified drug
עוד תגיות
תוכן קשור
More details
DOI :
10.1016/S0140-6736(02)07846-7
Article number:
Affiliations:
Database:
סקופוס
Publication Type:
מאמר
;
.
Language:
אנגלית
Editors' remarks:
ID:
30794
Last updated date:
02/03/2022 17:27
Creation date:
17/04/2018 00:57
You may also be interested in
Scientific Publication
Localisation of mesenchymal tumours by somatostatin receptor imaging
359
De Jan Beur, S.M., Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, United States
Streeten, E.A., Department of Medicine, University of Maryland, School of Medicine, Baltimore, MD, United States
Civelek, A.C., Department of Nuclear Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, United States
McCarthy, E.F., Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, United States
Uribe, L., Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, United States
Marx, S.J., Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, United States
Onobrakpeya, O., Department of Medicine, University of Connecticut Health Center, Farmington, CT, United States
Raisz, L.G., Department of Medicine, University of Connecticut Health Center, Farmington, CT, United States
Watts, N.B., Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, OH, United States
Sharon, M., Department of Medicine, Washington Hospital Center, Washington, DC, United States
Levine, M.A., Department of Pediatrics, Ilyssa Center for Molecular and Cellular Endocrinology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States
Localisation of mesenchymal tumours by somatostatin receptor imaging
Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.
Scientific Publication
נגישות
menu      
You may also be interested in